Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised open-label trial comparing intravenous iron and an erythropoiesis-stimulating agent versus oral iron to treat preoperative anaemia in cardiac surgery (INITIATE trial).
Kong R, Hutchinson N, Hill A, Ingoldby F, Skipper N, Jones C, Bremner S, Bruce C, Wright J, Lewis M, Newman S, Chevassut T, Hildick-Smith D. Kong R, et al. Among authors: chevassut t. Br J Anaesth. 2022 May;128(5):796-805. doi: 10.1016/j.bja.2022.01.034. Epub 2022 Mar 5. Br J Anaesth. 2022. PMID: 35256150 Free article. Clinical Trial.
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F, Roboz GJ, Wei AH, Döhner H, Pocock C, Selleslag D, Montesinos P, Sayar H, Musso M, Figuera-Alvarez A, Safah H, Tse W, Sohn SK, Hiwase D, Chevassut T, Pierdomenico F, La Torre I, Skikne B, Bailey R, Zhong J, Beach CL, Dombret H. Ravandi F, et al. Among authors: chevassut t. J Hematol Oncol. 2021 Aug 28;14(1):133. doi: 10.1186/s13045-021-01142-x. J Hematol Oncol. 2021. PMID: 34454540 Free PMC article. Clinical Trial.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
Knapper S, Chevassut T, Duarte R, Bergua JM, Salamero O, Johansen M, Jacobsen TF, Hals PA, Rasch W, Gianella-Borradori A, Smith M. Knapper S, et al. Among authors: chevassut t. Leuk Res. 2014 Mar;38(3):346-51. doi: 10.1016/j.leukres.2013.12.011. Epub 2013 Dec 25. Leuk Res. 2014. PMID: 24433865 Clinical Trial.
The Role of miRNA in Haematological Malignancy.
Gounaris-Shannon S, Chevassut T. Gounaris-Shannon S, et al. Among authors: chevassut t. Bone Marrow Res. 2013;2013:269107. doi: 10.1155/2013/269107. Epub 2013 Dec 12. Bone Marrow Res. 2013. PMID: 24416592 Free PMC article. Review.
A Novel In Vitro Model of the Bone Marrow Microenvironment in Acute Myeloid Leukemia Identifies CD44 and Focal Adhesion Kinase as Therapeutic Targets to Reverse Cell Adhesion-Mediated Drug Resistance.
Ladikou EE, Sharp K, Simoes FA, Jones JR, Burley T, Stott L, Vareli A, Kennedy E, Vause S, Chevassut T, Devi A, Ashworth I, Ross DM, Hartmann TN, Mitchell SA, Pepper CJ, Best G, Pepper AGS. Ladikou EE, et al. Among authors: chevassut t. Cancers (Basel). 2025 Jan 3;17(1):135. doi: 10.3390/cancers17010135. Cancers (Basel). 2025. PMID: 39796762 Free PMC article.
74 results